Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Ulf Bömer is active.

Publication


Featured researches published by Ulf Bömer.


ChemBioChem | 2005

High‐Throughput Screening for Kinase Inhibitors

Oliver von Ahsen; Ulf Bömer

Following G protein‐coupled receptors (GPCRs), protein kinases have become the second most important class of targets for drug discovery over the last 20 years. While only four kinase inhibitors have reached the market to date (Fasudil for rho‐dependent kinase, Rapamycin for TOR, Gleevec for BCR‐Abl, and Iressa for EGFR), many more are already in clinical development. A historical overview of kinase inhibitors was recently published by Cohen. 1 After the previous successes, protein kinases are now regarded as attractive, well‐drugable targets, and the analysis of the human genome has yielded 518 protein kinases. 2 We can thus expect screening for protein kinase inhibitors to become even more important in the future. In this review we will focus on the early steps of drug discovery programs producing new lead compounds. We will guide the reader through efficient state‐of‐the‐art assay development and high‐throughput screening of large chemical libraries for protein kinase inhibitors.


Journal of Biomolecular Screening | 2006

A Cost-Effective Solution to Reduce Dead Volume of a Standard Dispenser System by a Factor of 5

Christian Bergsdorf; Nadine Gewiese; Andreas Stolz; Rainer Mann; Karsten Parczyk; Ulf Bömer

A key trend in high-throughput screening is assay miniaturization to control reagent costs and increase throughput. For this purpose, liquid-handling devices are used that transfer nano-to low-microliter volumes into all currently used microtiter well plates. One drawback of many available dispenser and pipetting systems are high dead volumes. Therefore, the authors were looking for an easy and simple solution to modify their standard liquid-handling device, PerkinElmer’s FlexDrop™ Precision IV, allowing for a dead volume reduction to receive maximum benefit from miniaturized assay formats. Internal reservoirs were developed and constructed by Schering’s Technical Development Laboratory (TDL), which are directly connected to the dispenser banks of FlexDrop™ without tubing. Using these newly built reservoirs, the dead volume was decreased by a factor of 5 in comparison to the manufacturer’s reservoirs without compromising liquid-handling parameters such as accuracy and precision. The modified system displayed a high robustness and reliability under routine high-throughput screening conditions.


Archive | 2000

Ent-steroids as selectively active estrogens

Siegfried Schwarz; Dirk Kosemund; Gerd Müller; Margit Richter; Olaf Peters; Peter Droescher; Walter Elger; Alexander Hillisch; Ulf Bömer; Karl-Heinrich Fritzemeier; Christa Hegele-Hartung


Archive | 2014

SUBSTITUTED-IMIDAZO[1,2-B]PYRIDAZINES AS MKNK1 INHIBITORS

Knut Eis; Florian Pühler; Ludwig Zorn; Volker Schulze; Detlev Sülzle; Philip Lienau; Antje Margret Wengner; Kirstin Petersen; Ulf Bömer


Archive | 2000

16-hydroxyestratrienes as selective estrogens

Hermann Künzer; Rudolf Knauthe; Monika Lessl; Karl-Heinrich Fritzemeier; Christa Hegele-Hartung; Ulf Bömer; Gerd Müller; Dirk Kosemund


Archive | 2008

Novel 2-substituted tiazole-4-carboxamide derivatives, their preparation and use as pharmaceuticals

Ulrich Bothe; Ame Von Bonin; Duy Nguyen; Ulf Bömer; Judith Guenther


Archive | 2016

Combinations of inhibitors of irak4 with inhibitors of btk

Ulrich Bothe; Antje Margret Wengner; Holger Siebeneicher; Nicole Schmidt; Reinhard Nubbemeyer; Ulf Bömer; Judith Günther; Holger Steuber; Martin Lange; Christian Stegmann; Andreas Sutter; Roland Neuhaus


Archive | 2017

COMPUESTOS DE HETEROARILBENZIMIDAZOL

Horst Irlbacher; Wilhelm Bone; Volker Schulze; Tobias Heinrich; Julien Lefranc; Dra Anne Mengel; Florian Prinz; Dra Antje Wengner; Dra Clara Christ; Roman Hillig; Joszef Bálint; Hans Briem; Ulf Bömer; Detlef Stöckigt; Philip Lienau; Knut Eis; Marcus Koppitz; Benjamin Bader; Jens Schröder


Archive | 2017

imidazopiridazinas amino-substituídas

Arne Scholz; Florian Pühler; Judith Günther; Knut Eis; Ludwig Zorn; Marion Hitchcock; Mark Jean Gnoth; Philip Lienau; Ulf Bömer


Archive | 2017

Nuevos indazoles sustituidos, procedimientos para su preparación, preparaciones farmacéuticas que los contienen, así como su uso para la preparación de medicamentos.

Reinhard Nubbemeyer; Ulf Bömer; Christian Stegmann; Ulrich Bothe; Holger Siebeneicher; Nicole Schmidt; Holger Steuber; Judith Günther; Martin Lange; Andreas Sutter; Alexandra Rausch; Christian Friedrich; Peter Hauff

Collaboration


Dive into the Ulf Bömer's collaboration.

Top Co-Authors

Avatar

Philip Lienau

Bayer Schering Pharma AG

View shared research outputs
Top Co-Authors

Avatar

Arne Scholz

Humboldt University of Berlin

View shared research outputs
Top Co-Authors

Avatar

Dirk Kosemund

Bayer HealthCare Pharmaceuticals

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge